1
Clinical Trials associated with Graft-versus-host disease therapy(Applied StemCell, Inc.)Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro
Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. Furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.
Start Date20 Feb 2017 |
Sponsor / Collaborator- |
100 Clinical Results associated with Graft-versus-host disease therapy(Applied StemCell, Inc.)
100 Translational Medicine associated with Graft-versus-host disease therapy(Applied StemCell, Inc.)
100 Patents (Medical) associated with Graft-versus-host disease therapy(Applied StemCell, Inc.)
100 Deals associated with Graft-versus-host disease therapy(Applied StemCell, Inc.)